Assenagon Asset Management S.A. Has $32.78 Million Stock Position in Gilead Sciences, Inc. $GILD

Assenagon Asset Management S.A. lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 92.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 267,054 shares of the biopharmaceutical company’s stock after selling 3,222,008 shares during the period. Assenagon Asset Management S.A.’s holdings in Gilead Sciences were worth $32,778,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in GILD. Trivium Point Advisory LLC raised its position in Gilead Sciences by 1.1% during the third quarter. Trivium Point Advisory LLC now owns 7,325 shares of the biopharmaceutical company’s stock worth $813,000 after acquiring an additional 83 shares in the last quarter. Binnacle Investments Inc lifted its stake in Gilead Sciences by 11.8% in the 3rd quarter. Binnacle Investments Inc now owns 785 shares of the biopharmaceutical company’s stock valued at $87,000 after purchasing an additional 83 shares during the last quarter. Hemington Wealth Management lifted its stake in Gilead Sciences by 9.3% in the 3rd quarter. Hemington Wealth Management now owns 998 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 85 shares during the last quarter. Ignite Planners LLC grew its holdings in Gilead Sciences by 1.1% during the third quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company’s stock worth $880,000 after purchasing an additional 86 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. grew its holdings in Gilead Sciences by 0.3% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 34,711 shares of the biopharmaceutical company’s stock worth $3,912,000 after purchasing an additional 87 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $154.44, for a total transaction of $4,324,320.00. Following the completion of the sale, the insider owned 120,288 shares of the company’s stock, valued at approximately $18,577,278.72. This trade represents a 18.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total transaction of $617,500.00. Following the completion of the sale, the director directly owned 8,920 shares of the company’s stock, valued at approximately $1,101,620. The trade was a 35.92% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 309,280 shares of company stock worth $44,068,850 over the last quarter. 0.27% of the stock is currently owned by corporate insiders.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead agreed to acquire Arcellx in a large, strategic move to deepen its cell‑therapy franchise and obtain rights to anito‑cel; analyst commentary highlights anito‑cel as a meaningful revenue opportunity (GlobalData forecasts ~$658m sales by 2032), reinforcing the company’s long‑term growth story. Gilead doubles down on cell therapy
• Positive Sentiment: Gilead is buying Ouro Medicines for up to ~$2.18B to add OM336 (gamgertamig), a BCMAxCD3 T‑cell engager for autoimmune disease — a move that expands its inflammation/immunology pipeline and led to analyst and press coverage framing the deal as a second major bolt‑on after Arcellx. Gilead Eyes $2.2 Billion Autoimmune Push With Ouro Deal
• Positive Sentiment: Analyst/press takes (e.g., Barron’s, TipRanks) emphasize the strategic rationale — “immune reset” and broader immunology exposure — which likely bolstered investor confidence and buying interest following the deal announcements. Gilead to Buy Ouro Medicines for $2.2 Billion
• Neutral Sentiment: MaxCyte (a supplier/peer in cell therapy) reported a Q4 revenue miss — an industry data point investors may watch for supply or partner‑execution implications, but it does not directly change Gilead’s announced M&A strategy. MaxCyte Q4 Report
• Neutral Sentiment: Several short‑interest reports posted for March show large increases but contain erroneous/zeroed values (NaN/0), so there’s no clear short‑pressure signal to explain moves; treat the data as unreliable until exchanges update filings.
• Neutral Sentiment: Other sector news (Weave Bio advisory board, broad market mover roundups) is background noise and unlikely to be a primary driver of GILD’s intraday move. Weave Bio Advisory Board

Wall Street Analyst Weigh In

Several analysts have issued reports on GILD shares. Citigroup restated a “buy” rating on shares of Gilead Sciences in a research note on Friday, March 6th. Scotiabank lifted their target price on Gilead Sciences from $140.00 to $177.00 and gave the stock a “sector outperform” rating in a research note on Wednesday, February 11th. Wells Fargo & Company boosted their target price on Gilead Sciences from $150.00 to $165.00 and gave the stock an “overweight” rating in a report on Wednesday, February 11th. Cantor Fitzgerald increased their price target on Gilead Sciences from $135.00 to $155.00 and gave the company an “overweight” rating in a research note on Wednesday, February 11th. Finally, Royal Bank Of Canada raised their price target on Gilead Sciences from $103.00 to $118.00 and gave the company a “sector perform” rating in a report on Wednesday, February 11th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $157.62.

Gilead Sciences Trading Up 0.1%

Shares of GILD stock opened at $138.26 on Thursday. The firm has a 50 day moving average price of $143.59 and a two-hundred day moving average price of $128.39. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98. The company has a market capitalization of $171.61 billion, a PE ratio of 20.42, a price-to-earnings-growth ratio of 1.81 and a beta of 0.37. Gilead Sciences, Inc. has a 12-month low of $93.37 and a 12-month high of $157.29.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. The company had revenue of $7.93 billion during the quarter, compared to analysts’ expectations of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The business’s revenue was up 4.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be given a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.4%. The ex-dividend date is Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s dividend payout ratio (DPR) is 48.45%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.